Noteworthy

Dec 01, 2010
Pharmaceutical Executive
Pharm Exec's Pipeline Report 2022
Dec 01, 2010
Pharmaceutical Executive
By Pharmaceutical Executive Editors
Outgoing EMA Director Thomas Lonngren discusses a decade at the helm of Europe's top regulatory office
Dec 01, 2010
Pharmaceutical Executive
Pharm Exec's Pipeline Report 2013
Dec 01, 2010
Pharmaceutical Executive
Putting science front-and-center in the design of patient adherence programs can lead to a better understanding of the commitment required to get patients to take their medicine
Dec 01, 2010
Pharmaceutical Executive
Pharm Exec's Pipeline Report 2011
Dec 01, 2010
Pharmaceutical Executive
Pharm Exec's Pipeline Report 2020
Dec 01, 2010
Pharmaceutical Executive
Republican gains in Congress create uncertainty for health reform, drug regulation, and biomedical research
Dec 01, 2010
Pharmaceutical Executive
Stepped-up enforcement of the Foreign Corrupt Practices Act requires enhanced global coordination of compliance
Dec 01, 2010
Pharmaceutical Executive
Pharm Exec's Pipeline Report 2023
Dec 01, 2010
Pharmaceutical Executive
The end of anther year is an appropriate time to highlight the march of time—and the transitions that accompany it
native1_300x100
lorem ipsum